Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Long-Term Investments (2016 - 2025)

Tg Therapeutics (TGTX) has 5 years of Long-Term Investments data on record, last reported at $59.1 million in Q4 2025.

  • For Q4 2025, Long-Term Investments rose 7218.81% year-over-year to $59.1 million; the TTM value through Dec 2025 reached $59.1 million, up 7218.81%, while the annual FY2025 figure was $59.1 million, 7218.81% up from the prior year.
  • Long-Term Investments reached $59.1 million in Q4 2025 per TGTX's latest filing, up from $48.8 million in the prior quarter.
  • Across five years, Long-Term Investments topped out at $59.1 million in Q4 2025 and bottomed at $808000.0 in Q4 2024.
  • Average Long-Term Investments over 4 years is $22.2 million, with a median of $21.8 million recorded in 2022.
  • Peak YoY movement for Long-Term Investments: plummeted 65.09% in 2022, then skyrocketed 7218.81% in 2025.
  • A 4-year view of Long-Term Investments shows it stood at $35.5 million in 2021, then tumbled by 65.09% to $12.4 million in 2022, then crashed by 93.49% to $808000.0 in 2024, then surged by 7218.81% to $59.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Long-Term Investments were $59.1 million in Q4 2025, $48.8 million in Q3 2025, and $28.6 million in Q2 2025.